Skip to content
PhageCocktails
ClinicalListeria / Salmonella / E. coli O157Target #49 of 50

Food-safety biocontrol

Listeria monocytogenes, Salmonella enterica, and Shiga toxin-producing E. coli O157:H7 are leading causes of foodborne illness, recalls, and deaths, and they persist on ready-to-eat (RTE) foods, fresh produce, raw meat, and food-contact surfaces where conventional sanitizers and antibiotics are unsuitable or incompletely effective. L. monocytogenes is especially dangerous because it grows at refrigeration temperatures and forms biofilms in processing plants, while E. coli O157:H7 has a very low infectious dose. Lytic bacteriophages are an attractive biocontrol tool here because they are exquisitely host-specific (killing the target pathogen without disturbing beneficial microbiota, fermentation cultures, or food organoleptics), self-amplify as long as host bacteria are present, and are "clean-label," GRAS-recognized, and leave no chemical residue. This is the single most regulatory-mature application of phages anywhere: it is already commercialized and FDA-cleared, not experimental.

How phages act here

Mechanism

Phages adsorb to specific surface receptors on the target strain, inject their genome, hijack host machinery to replicate, and lyse the cell — a mechanism unaffected by antibiotic-resistance status, which is why STEC O157:H7 and even ESBL-producing E. coli are valid targets. Because any single phage covers only a subset of strains, products are formulated as cocktails (e.g., six phages) to broaden coverage across serovars/serotypes and to suppress emergence of phage-insensitive bacterial mutants (BIMs), which do arise on food matrices. Phages and their tail-associated depolymerases plus endolysins can penetrate and degrade the extracellular matrix of biofilms in processing environments, a niche where Listeria notoriously persists; phage-derived endolysins are being explored as standalone biofilm-clearing enzymes. Applications include direct surface spraying of RTE foods, produce, and carcasses, incorporation into active food-packaging films/coatings, and surface decontamination, with documented 1–4 log reductions; engineered and CRISPR-armed phages (e.g., to re-sensitize or sequence-specifically kill target strains) are an emerging research angle but not yet the basis of marketed food products.

Where it stands

Current evidence

This is a commercially deployed, FDA-regulated technology rather than a clinical-trial-stage one. Intralytix's ListShield (six-phage anti-Listeria cocktail) was cleared by FDA in 2006 as a food additive under 21 CFR 172.785 — the first phage product ever approved for food — and received GRAS recognition in 2015 for direct application to fish/shellfish, fruits, vegetables, and dairy; a 2015 peer-reviewed study showed it reduced or eliminated L. monocytogenes on lettuce, apples, cheese, smoked salmon, and frozen foods (0.7–2.2 log reductions). Micreos/PhageGuard's Listex P100 received an FDA no-objection GRAS letter (and a 2016 EFSA evaluation) for Listeria on RTE foods. For Salmonella, Intralytix's SalmoFresh and PhageGuard S hold GRAS status (SalmoFresh = GRN 435) for produce, seafood, and poultry; a six-phage Salmonella cocktail showed >95% in vitro coverage of 930 strains across 44 serovars and reduced Salmonella in dried pet food (Heyse et al., 2015), and a 2024 study validated a three-phage cocktail in food matrices, biofilm, and broiler chickens. For E. coli O157:H7, EcoShield is marketed for red meat, and multiple peer-reviewed studies (e.g., on beef) demonstrate 1–4 log reductions, including simultaneous control of O157:H7 and ESBL E. coli. Products are Kosher/Halal-certified and many are OMRI-listed for organic use; Intralytix reported reaching profitability in 2024.

Evidence confidence: high

The data

Key studies & trials

Who is working on it

Programs & centers

Intralytix, Inc. (ListShield, SalmoFresh, EcoShield, ShigaShield)Micreos / PhageGuard (PhageGuard Listex P100, PhageGuard S)U.S. FDA Center for Food Safety and Applied Nutrition (food additive 21 CFR 172.785; GRAS Notices, e.g., GRN 435)EFSA (European Food Safety Authority) — Listex P100 safety/efficacy evaluationAgriculture and Agri-Food Canada / University of Lethbridge (foodborne phage biocontrol research)

The possibility

Phage biocontrol is poised to become a routine, invisible layer of food safety — a clean-label spray or packaging film that quietly intercepts Listeria, Salmonella, and E. coli O157 from farm to fork without altering taste, texture, or the "organic" label. As genomic surveillance lets producers match phage cocktails to the exact strains circulating in a given plant or region, treatments could become adaptive and even personalized to a facility's resident flora, with endolysin enzymes and CRISPR-guided phages added to crack open the biofilms that make processing lines so hard to sanitize. In a world of rising antibiotic resistance and consumer demand for chemical-free preservation, these self-amplifying, precision antimicrobials may shift food safety from blunt chemical washes toward a living, targeted defense that scales up exactly when and where contamination appears.

Scientific & educational content. As of 2026 no bacteriophage therapeutic is approved as a marketed drug in the United States or European Union. Phage therapy is available only through clinical trials, compassionate-use / expanded-access pathways, and national magistral frameworks. Nothing here is medical advice or an offer to sell a therapeutic.